- 4-Week # shares sold: 15,000
- 12-Week # shares sold: 17,678
- 24-Week # shares sold: 32,365
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.
In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.